N-Power Medicine
Clinical research technology company for community oncology, N-Power Medicine runs an always-on system boosting trial participation with prospective external controls.
- Private company
- Redwood City, CA, USUnited States
Clinical research technology company for community oncology, N-Power Medicine runs an always-on system boosting trial participation with prospective external controls.
npowermedicine.comCrawled Nov 2, 2026
The page features peer-reviewed publications by the company’s team and research partners.
The page lists press releases, publications, and articles on clinical research and oncology.
N-Power Medicine is building the first always-on clinical research system in community oncology to dramatically boost clinical trial participation and realize the promise of prospective external controls to accelerate and de-risk oncology R&D.
The company aims to accelerate and improve predictability in drug development.
Where research is part of every oncologist’s practice and every patient’s care.
N-Power Medicine’s Privacy Policy outlines how it collects, uses, and shares personal information on its website.
N-Power Medicine secures a **$32 million Series B** to advance its oncology research. The round includes investments from **Innovatus Capital Partners**, **Labcorp Venture Fund**, and **Merck Global Health Innovation Fund**. The funding will support further development of its therapeutic approaches in cancer treatment.
Oct 2026RoundOSNews article
N-Power Medicine partners with New York Cancer & Blood Specialists (NYCBS) to accelerate the development of its Prospective External Control Arms (ProECAs). This collaboration aims to streamline oncology clinical trials by reducing trial size and expediting patient access to new therapies. NYCBS, a leading independent oncology practice, contributes its expertise in clinical research to support the initiative.
Oct 2026citybizNews article
N-Power Medicine secures $32 million in funding to advance research focused on community oncology. The investment supports efforts to improve cancer care access and outcomes in underserved settings. The company targets gaps in treatment and diagnostics for oncology patients outside major academic centers.
Sep 2026Fundraise InsiderNews article
N-Power Medicine secures **$32 million in Series B funding** to grow its **community oncology network** and **ProECA platform**. Investors include **Labcorp Venture Fund**, **Merck Global Health Innovation Fund**, and **Innovatus Capital Partners**. The round supports expansion of precision oncology services in underserved markets.
Sep 2026MedPath TrialNews article